KEGG   DRUG: Izuralimab
Entry
D12195                      Drug                                   
Name
Izuralimab (USAN)
Formula
C5622H8636N1502O1738S38
Exact mass
126214.2944
Mol weight
126292.2158
Sequence
(Chain A)
EIVLTQSPAT LSASPGERVT LTCRASQSVG NDVAWYQQKP GQAPRLLINY ASHRYTGVPD
RFTGSGYGTE FTLTISSVQS EDFGVYYCQQ DFSSPRTFGG GTKVEIKGKP GSGKPGSGKP
GSGKPGSEVQ LVESGGGLVK PGGSLRLSCV ASGFTFSNYW MNWVRQAPGK GLEWVAEIRL
YSNNYATHYA ESVKGRFTIS RDDSKSTLYL QMNNLKTEDT GVYYCTRYYG NYGGYFDVWG
RGTLVTVSSE PKSSDKTHTC PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA
 LPAPIEKTIS KAKGQPREPQ VYTLPPSREQ MTKNQVKLTC LVKGFYPSDI
AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT
QKSLSLSPGK
(Chain B)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW INPHSGGTNY
AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARTY YYDSSGYYHD AFDIWGQGTM
VTVSSASTKG PSVFPLAPSS KSTSGGTAA GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSDTKVD KKVEPKSCDK THTCPPCPAP
PVAGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVKHEDPEV KFNWYVDGVE VHNAKTKPRE
EEYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
SREEMTKNQV SLTCDVSGFY PSDIAVEWES DGQPENNYKT TPPVLDSDGS FFLYSKLTVD
KSRWEQGDVF SCSVLHEALH SHYTQKSLSL SPGK
(Chain C)
DIQMTQSPSS VSASVGDRVT ITCRASQGIS RLLAWYQQKP GKAPKLLIYV ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPWTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A23-A88, A149-A225, A260-B234, A263-B237, A294-A354, A400-A458, B22-B96, B152-B208, B228-C214, B268-B328, B374-B432, C23-C88, C134-C194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immunomodulator
Comment
Monoclonal antibody
Target
ICOS (CD278) [HSA:29851] [KO:K06713]
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa04672  Intestinal immune network for IgA production
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12195  Izuralimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D12195  Izuralimab (USAN)
   CD molecules
    ICOS (CD278)
     D12195  Izuralimab (USAN)
Other DBs
CAS: 2329669-80-7

» Japanese version   » Back

DBGET integrated database retrieval system